… , gefitinib (17, 18), we performed mutational profiling of exons 18-24 of EGFR in tumors from
10 patients … exons 18-24 in 8 and 10 patients refractory to gefitinib and erlotinib, respectively. …

… After excluding ineligible patients, the remaining 5975 patients constituted our study cohort,
including 4340 in the gefitinib cohort and 1635 in the erlotinib cohort. The TKI cohorts were …

… first-line erlotinib or gefitinib with cytotoxic chemotherapy in patients with … patients and the
EURTAC trial in Caucasian patients clearly demonstrated the superiority of erlotinib or gefitinib …

… gefitinib [17]. We retrospectively studied gefitinib-resistant NSCLC p atients treated with erlotinib
… disease control (DC) rates of patients who received erlotinib after failure of long SD with …

… In this current case we demonstrated the first cross-over response to erlotinib after gefitinib
failure in a patient with an activating EGFR mutation. Serial sections on the CT scan disclosed …

… After restarting erlotinib or gefitinib in these patients, tumors … now recommend continued
erlotinib in patients with acquired … protocol to allow patients to continue erlotinib in addition to …

… The patient in this case … gefitinib, 8,9,10 successful treatment of leptomeningeal metastasis
has not been reported. Furthermore, in patients who have a response to gefitinib or erlotinib …

… The patients included in this study represent all of the patients from our institution who met
… on treatment with gefitinib or erlotinib before March 2005. Patients were identified through a …

… In a retrospective analysis comparing the effectiveness of erlotinib and gefitinib in patients
with EGFR wild-type NSCLC, there are no differences in response rate or survival rate …

… We investigated the incidence of ILD in Japanese patients treated with gefitinib or erlotinib.
… in Japanese patients with NSCLC who were treated with gefitinib or erlotinib monotherapy in …